Table 1 Baseline characteristics of the patients with episodic cluster headache according to the timing of 240 mg of galcanezumab therapy (GT)
From: Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache
GT add-on CPT (n = 36) | Initial GT (n = 11)a | P-value | |
|---|---|---|---|
Age, years | 40.1 ± 8.7 | 41.5 ± 9.4 | 0.68 |
Male sex, n (%) | 29 (80.6) | 10 (90.9) | 0.73 |
Onset age, years | 29.5 (22.0, 35.3) | 24 (20.0, 29.5) | 0.20 |
Duration of CH disease, years | 8.5 (5.0, 12.5) | 10 (8.0, 21.5) | 0.07 |
Average duration of cluster period, weeks | 6 (5.0, 8.0) | 8 (4.5, 10.0) | 0.67 |
time to GT from the onset of cluster bout, days | 19 (13.2, 28.2) | 9.0 (8.5, 23.5) | 0.23 |
BMI, kg/m2 | 24.3 ± 4.3 | 23.5 ± 1.9 | 0.41 |
Ever-smoker, n (%) | 22 (61.1) | 7 (63.6) | 1.00 |
Current alcohol drinking, n (%) | 19 (52.7) | 7 (63.9) | 1.00 |
Comorbid migraine, n (%) | 11 (30.4) | 2 (18.2) | 0.68 |
PHQ-9 score* | 7.9 ± 6.6 | 9.9 ± 7.3 | 0.50 |
GAD-7 score* | 8.5 ± 5.5 | 10.6 ± 7.2 | 0.42 |
EQ-5d scores* | 0.91 (0.86, 1.00) | 0.84 (0.79, 0.94) | 0.46 |
Passive suicidal idea* | 70.5% | 87.5% | 0.62 |
Abortive treatment | |||
Oxygen, n (%) | 10 (27.8) | 3 (27.2) | 1.00 |
Triptan, n (%) | 29 (80.6) | 4 (36.4) | 0.26 |
CPT | |||
Verapamil, n (%) | 27 (75.0) | – | |
Lithium, n (%) | 6 (16.7) | – | |
Prednisolone, n (%) | 26 (72.2) | – | |
Occipital nerve block, n (%) | 23 (63.9) | – | |
Topiramate, n (%) | 14 (38.9) | – |